Journals / Eurasian Journal of Medical Investigation / 2020 / Cilt: 4 - Sayı: 3

Development of Venous Thromboembolism in Patients with Hereditary Thrombophilic Risk Factors and Evaluation of Genetic and Biochemical Parameters Affecting Development of Venous Thromboembolism

Pages
304–311
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Elevated homocysteine was higher in study group compared to controls, and the difference was statistically significant (p=0.02).Conclusion: Determination of hereditary risk factors in VTE patients will provide family members who have hereditary risk factors, but did not suffer attack to be protected against thromboembolic attacks by taking simple measuresagainst acquired factors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate patients diagnosed with venous thromboembolism (VTE) in terms of hereditary thrombophilicrisk factors and to assess genetic and biochemical factors affecting the development of VTE.Methods: Sixty patients with VTE and 23 control subjects without VTE were retrospectively evaluated.
📊
Key Findings & Data:Prevalence ofthrombophilic risk factors and parameters like demographic data, clinical follow-up duration were examined with genetic, biochemical and radiological investigations.Results: Mutations were detected in the genes of Factor V Leiden in 37.4%, Factor II in 13.4%, Methylenetetrahydrofolate reductase C677 in 47.5%, Methylenetetrahydrofolate reductase A1298C in 53.3%, Plasminogen activator inhibitor-1 in 31.6%, Angiotensin converting enzyme in 39.0%, and Factor V H1299R in 8.3% of patients.
💡
Conclusion & Impact:Elevated homocysteine was higher in study group compared to controls, and the difference was statistically significant (p=0.02).Conclusion: Determination of hereditary risk factors in VTE patients will provide family members who have hereditary risk factors, but did not suffer attack to be protected against thromboembolic attacks by taking simple measuresagainst acquired factors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate patients diagnosed with venous thromboembolism (VTE) in terms of hereditary thrombophilicrisk factors and to assess genetic and biochemical factors affecting the development of VTE.Methods: Sixty patients with VTE and 23 control subjects without VTE were retrospectively evaluated. Prevalence ofthrombophilic risk factors and parameters like demographic data, clinical follow-up duration were examined with genetic, biochemical and radiological investigations.Results: Mutations were detected in the genes of Factor V Leiden in 37.4%, Factor II in 13.4%, Methylenetetrahydrofolate reductase C677 in 47.5%, Methylenetetrahydrofolate reductase A1298C in 53.3%, Plasminogen activator inhibitor-1 in 31.6%, Angiotensin converting enzyme in 39.0%, and Factor V H1299R in 8.3% of patients. Protein C deficiencywas detected in 25 patients (41.7%), free Protein S deficiency was detected in 25 patients (41.7%) in study group and 3subjects (13.0%) in control group, and this difference was statistically significant (p=0.023). Antithrombin III deficiencywas detected in 1 patient (1.7%) in study group. Elevated homocysteine was higher in study group compared to controls, and the difference was statistically significant (p=0.02).Conclusion: Determination of hereditary risk factors in VTE patients will provide family members who have hereditary risk factors, but did not suffer attack to be protected against thromboembolic attacks by taking simple measuresagainst acquired factors.

🔖

Cite This Article

VELİOĞLU, Y., YÜKSEL, A., KORKMAZ, U. T. K., UÇAROĞLU, E. R., ERDEM, K., DAĞLAR, B., ARSLAN, A. O., DÜZENLİ, S., ÇETİNKAYA, A. (2022). Development of Venous Thromboembolism in Patients with Hereditary Thrombophilic Risk Factors and Evaluation of Genetic and Biochemical Parameters Affecting Development of Venous Thromboembolism. Eurasian Journal of Medical Investigation, Cilt: 4 - Sayı: 3, 304–311. https://ajindex.com/articles/508699

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Schulman S, Ageno W, Konstantinides SV. Venous thromboembolism: Past, present and future. Thromb Haemost 2017;117:1219–29
  2. Yuksel A, Tuydes O. Midterm outcomes of pharmacomechanical thrombectomy in the treatment of lower extremity deep vein thrombosis with a rotational thrombectomy device. Vasc Endovascular Surg 2017;51:301–6
  3. Tok M, Tuydes O, Kan II, Yuksel A, Yolgosteren A. Our earlyresults for the treatment of acute and subacute iliofemoral deep vein thrombosis with rotational thrombectomy catheter. Turk J Vasc Surg 2014;23:169–75
  4. Atahan A, Çağlar E, Şarkış C, Uğurlu S. Venous thromboembo- lism and inherited thrombophilia. Turkish J Thorac Cardiovasc Surg 2009;17:302–11
  5. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001;109:369–84
  6. Robetoyre RS, Rodgers GM. Update on selected inherited venous thrombotic disorders. Am J Hematol 2001;68:256–68
  7. Jadaon MM. Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region. Mediterr J Hematol Infect Dis 2011;3:e2011037
  8. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503–6
  9. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912–7
  10. Caprini JA, Goldshteyn S, Glase CJ, Hathaway K. Thrombophilia testing in patients with venous thrombosis. Eur J Vasc Endovasc Surg 2005;30:550–5
  11. Bushnell CD, Goldstein LB. Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000;31:3067– 78
  12. Altıntaş A, Çil T, Kaplan MA, et al. Hereditary thrombophilic risk factors in patients with deep venous thrombosis. UHOD 2007;17:65–9
  13. Roldan V, Lecumberri R, Muñoz-Torrero JF, et al. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res 2009;124:174–7
  14. Chen CH, Eng HL, Chang CJ, et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med 2003;142:100–5
  15. Philipp CS, Dilley A, Saidi P, et al. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost 1998;80:869– 73
  16. Kreidy R. Influence of acquired and genetic risk factors on